Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Full Approval To VITRAKVI for NTRK Fusion Solid Tumors
Details : Vitrakvi (larotrectinib sulfate) is an inhibitor of the TRKA, TRKB, and TRKC. It is approved for the treatment of adult and pediatric patients with ntrk gene fusion-positive solid tumors.
Product Name : Vitrakvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2019
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2017
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2015
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2014
Lead Product(s) : Larotrectinib Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
